MelanoSITE™
Record ID 32012000123
English
Authors' recommendations:
It has been estimated that, in 2011, more than 70,000 individuals in the United States were diagnosed with melanoma, a malignant tumor of pigment-producing melanocyte cells. Of these cases, nearly 8800 people are expected to have died from the disease. While melanoma represents only 7% of skin malignancies, it represents approximately 75% of all skin cancer–related deaths. While localized, melanoma may be successfully treated by complete excision. Once the disease has metastasized, however, the condition becomes quite difficult to treat. Histopathological evaluation of the excised lesion is the current reference standard for the diagnosis of suspicious melanocytic growths. While most lesions may be readily diagnosed by standard histopathology, some may be difficult to classify as either malignant melanoma or benign nevus because of the presence of ambiguous or borderline histopathological findings. The MelanoSITE test was developed to facilitate the diagnosis of these ambiguous lesions. The analysis is based on the fact that most malignant melanomas demonstrate signs of genomic instability, indicated by the presence of specific chromosomal gains and losses, while most benign nevi do not. The MelanoSITE test utilizes fluorescence in situ hybridization (FISH) to evaluate the copy number of three genes: RREB1 (ras responsive element binding protein 1 gene) at 6p25, MYB (v-myb myeloblastosis viral oncogene homolog) at 6q23, and CCND1 (cyclin D1 gene) at 11q13; and the chromosome 6 centromere (CEN6). This four-probe FISH assay allows visualization of chromosomal gains and losses involving these four loci.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=13430
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Melanoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.